No announcement yet.

A novel fluorescent and bioluminescent Bi-Reporter influenza A virus (BIRFLU) to evaluate viral infections

  • Filter
  • Time
  • Show
Clear All
new posts

  • A novel fluorescent and bioluminescent Bi-Reporter influenza A virus (BIRFLU) to evaluate viral infections

    J Virol. 2019 Mar 13. pii: JVI.00032-19. doi: 10.1128/JVI.00032-19. [Epub ahead of print]
    A novel fluorescent and bioluminescent Bi-Reporter influenza A virus (BIRFLU) to evaluate viral infections.

    Nogales A1,2, ?vila-P?rez G1, Rangel-Moreno J3, Chiem K1, DeDiego ML4, Mart?nez-Sobrido L5.
    Author information


    Studying influenza A virus (IAV) requires the use of secondary approaches to detect the presence of virus in infected cells. To overcome this problem, we and others have generated recombinant IAV expressing fluorescent or luciferase reporter genes. These foreign reporter genes can be used as valid surrogates to track the presence of virus. However, the limited capacity for incorporating foreign sequences in the viral genome forced researchers to select fluorescent or luciferase, depending on the type of study. To circumvent this limitation, we have engineered a novel recombinant replication-competent bi-reporter IAV (BIRFLU), expressing both fluorescent and luciferase reporter genes. In cultured cells, BIRFLU displayed comparable growth kinetics to wild-type (WT) virus and was used to screen neutralizing antibodies or compounds with antiviral activity. The expression of two reporter genes allows to monitor viral inhibition by fluorescence or bioluminescence, overcoming limitations associated with the use of one reporter gene as a readout. In vivo, BIRFLU effectively infected mice and both reporter genes were detected using in vivo imaging systems (IVIS). The ability to generate recombinant IAV harboring multiple foreign genes opens unique possibilities for studying virus-host interactions and for using IAV in high-throughput screenings (HTS) to identify novel antivirals that can be incorporated into the therapeutic armamentarium to control IAV infections. Moreover, the ability to genetically manipulate the viral genome to express two foreign genes offers the possibility of developing novel influenza vaccines and the feasibility for using recombinant IAV as vaccine vectors to treat other pathogen infections.IMPORTANCE The influenza A virus (IAV) causes human respiratory disease that is associated with significant health and economic consequences. In recent years, the use of replication-competent IAV expressing an easily traceable reporter fluorescent or luciferase protein has significantly contributed to progress in influenza research. However, researchers have been forced to select a fluorescent or a luciferase reporter gene due to the restricted capacity of the influenza viral genome for including foreign sequences. To overcome this limitation, we have generated, for the first time, a recombinant replication-competent bi-reporter IAV (BIRFLU) that stably expresses two reporter genes (one fluorescent and one luciferase) to track IAV infections in vitro and in vivo The combination of cutting edge techniques from molecular biology, animal research and imaging technologies brings researchers the unique opportunity to use this new generation of reporter-expressing IAV to study viral infection dynamics in both cultured cells and animal models of viral infection.
    Copyright ? 2019 American Society for Microbiology.

    PMID: 30867298 DOI: 10.1128/JVI.00032-19